Abstract
Objective: ONC201 is a well-tolerated, orally active small molecule that demonstrated promising activity in patients with advanced endometrial cancer in a phase I clinical trial and is now being tested as a single agent in phase II trials. ONC201 activates the integrated stress response (ISR) and upregulates TRAIL and its receptor DR5. We hypothesized that ONC201 upregulation of DR5 could sensitize tumor cells to TRAIL and that the combination of ONC201 and TRAIL would lead to enhanced cell death in endometrial cancer models
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
